duloxetine mylan
mylan pharmaceuticals limited - duloksetinas - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - gydant didžiosios depresijos sutrikimas;gydymo cukriniu diabetu periferinis neuropatinis skausmas;gydant generalizuoto nerimo sutrikimas;duloxetine mylan yra nurodyta suaugusieji.
lopinavir/ritonavir mylan
mylan pharmaceuticals limited - lopinavir, ritonaviru - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - lopinaviro/ritonaviro skiriamas kartu su kitais antiretrovirusiniais vaistiniais preparatais gydant žmogaus imunodeficito viruso (Živ-1) infekuotiems suaugusiesiems, paaugliams ir vyresniems nei 2 metų amžiaus. pasirinkimas lopinavir/ritonaviru gydyti proteazė inhibitorius patyręs Živ-1 infekuotiems pacientams, kuriems turėtų būti grindžiamas atskirų virusinės rezistencijos tyrimų ir gydymo pacientų istorijos.
bimatoprost/timolol mylan
mylan pharmaceuticals limited - bimatoprostas/timololis - akių lašai (tirpalas) - 0,3 mg/5 mg/ml - timolol, combinations
ivabradine mylan
mylan pharmaceuticals limited - ivabradinas - plėvele dengtos tabletės - 7,5 mg; 5 mg - ivabradine
travoprost/timolol mylan
mylan pharmaceuticals limited - travoprostas/timololis - akių lašai (tirpalas) - 40 µg/5 mg/ml - timolol, combinations
agomelatine mylan
mylan pharmaceuticals limited - agomelatinas - plėvele dengtos tabletės - 25 mg - agomelatine
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrelio hidrochloridas - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboziniai vaistai - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
femoston
viatris sia - estradiolis+estradiolis/didrogesteronas - plėvele dengtos tabletės - 1 mg + 1 mg/10 mg - dydrogesterone and estrogen
femoston conti
viatris sia - estradiolis/didrogesteronas - plėvele dengtos tabletės - 1 mg/5 mg - dydrogesterone and estrogen
gopten
viatris sia - trandolaprilis - kietosios kapsulės - 2 mg; 4 mg - trandolapril